Impact of Linked Color Imaging on Sessile Serrated Lesion Miss Rate

NCT07745842 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 2072

Last updated 2026-08-04

No results posted yet for this study

Summary

This prospective, multicenter randomized controlled trial aimed to investigate whether linked color imaging (LCI) could reduce the miss rate of sessile serrated lesions (SSLs) during tandem colonoscopy compared with conventional white-light imaging (WLI).

Conditions

  • Colorectal Sessile Serrated Lesion

Interventions

PROCEDURE

WLI Then LCI Withdrawal

Patients in the WLI then LCI withdrawal group first underwent careful endoscopic inspection with white-light imaging (WLI). The endoscopic setting was then switched to linked color imaging (LCI) for the second withdrawal. All polyps detected during both inspection passes were resected, and the number of lesions missed on the first withdrawal was subsequently calculated.

PROCEDURE

LCI Then WLI Withdrawal

Patients in the LCI then WLI withdrawal group first underwent careful endoscopic inspection with linked color imaging (LCI). The endoscopic setting was then switched to white-light imaging (WLI) for the second withdrawal. All polyps detected during both inspection passes were resected, and the number of lesions missed on the first withdrawal was subsequently calculated.

Sponsors & Collaborators

  • Shunde First People's Hospital of Foshan

    collaborator UNKNOWN
  • ZhuHai Hospital

    collaborator OTHER
  • Jiangmen Central Hospital

    collaborator OTHER
  • Yangjiang People's Hospital

    collaborator OTHER
  • Zhongshan Guzhen People's Hospital

    collaborator UNKNOWN
  • Sihui Wanlong Hospital

    collaborator UNKNOWN
  • The Third People's Hospital of Huizhou

    collaborator OTHER
  • Longgang District People's Hospital of Shenzhen

    collaborator OTHER
  • Suixi People's Hospital of Zhanjiang

    collaborator UNKNOWN
  • Nanfang Hospital, Southern Medical University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-08-31
Primary Completion
2028-11-30
Completion
2029-02-28

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07745842 on ClinicalTrials.gov